Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels

Thrombosis and Haemostasis

Volumn 101, Issue 2, 2009, Pages 312-316

  De La Red, Gloria ^a   Tàssies, Dolores ^b   Espinosa, Gerard ^a   Monteagudo, Joan ^b   Bové, Albert ^a   Plaza, Joan ^a   Cervera, Ricard ^a   Reverter, Joan Carles ^b  

^a Institut de Medicina i Salut   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiphospholipid antibodies; Factor XIII polymorphism; Fibrinogen; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 13A; FIBRINOGEN; PHOSPHOLIPID ANTIBODY; BLOOD CLOTTING FACTOR 13; FACTOR XIII SUBUNIT A; LEUCINE; PROTEIN SUBUNIT; VALINE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; RISK; RISK ASSESSMENT; UPREGULATION;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; FACTOR XIII; FEMALE; FIBRINOGEN; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUCINE; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; PROTEIN SUBUNITS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; UP-REGULATION; VALINE;

EID: 62449126466     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-06-0347     Document Type: Article

References (35)

1. rd ed, Churchill Livingstone 1994: 531-546.
2. Schwartz ML, Pizzo SV, Hill RL, et al. Human factor XIII from plasma and platelets: molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1395-1407.
3. Mikkola H, Syrjälä M, Rasi V, et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84: 517-525.
4. Kohler HP, Stickland HM, Ossei-Gerning N, et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
5. Shafey M, Anderson JL, Scarvelis D, et al. Factor XIII Va134Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 2007; 97: 635-641.
6. Vokó Z, Bereczky Z, Katona E, et al. Factor XIII Va134Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost 2007; 97: 458-463.
7. Rallidis LS, Politou M, Komporozos C, et al. Factor XIII Va134Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
8. Elbaz A, Poirier O, Canaple S, et al. The association between the Va134Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-591.
9. Slowik A, Dziedzic T, Pera J, et al. Coagulation factor XIII in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis 2005; 19: 165-170.
10. Catto AJ, Kohler HP, Mansfield MW, et al. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-908.
11. Franco RE Reistma PH. Lourenco D, et al. Factor XIII Va134Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81: 676-679.
12. Rentier W, Koppel H, Hoffmann C, et al. Prothrombin G20210A, factor V Leiden, and factor XIII Val 34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res 2000: 99: 35-39.
13. Zidane M, de Visser MC, ten Wolde M, et al. Frequency of the TAFT-438 G/A and factor XIIIA Va134Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb Haemost 2003; 90: 439-445.
14. Van Hylckama Vlieg A, Komanasin N, Ariens RA, et al. Factor XIII Va134Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119: 169-175.
15. Ariens RAS, Philippou H, Nagaswami C, et al. The factor XIIIV34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
16. Corral J, Gonzalez-Conejero R, Iniesta JA, et al. The FXIII Va134Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-297.
17. Roldan V, Corral J, Marin F, et al. Role of factor XIII Va134Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am J Cardiol 2003; 91: 1242-1245.
18. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; l07: 1117-1122.
19. Lim BCB, Ariens RA, Carter AM, et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
20. Salmon J, de Groot D. Pathogenic role of antiphosp-holipid antibodies. Lupus 2008; 17: 405-411.
21. Diz-Kucukkaya R, HancerVS, Inanc M, et al. Factor XIII Va134Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus 2004; 13: 32-35.
22. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulant: an update. Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
23. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). I Thromb Haemost 2006; 4: 295-306.
24. Tan EM, CohenAS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
25. Henry M, Morange PE, Canavy I, et al. Rapid detection of factor XIII Va134Leu by allele specific PCR. Thromb Haemost 1999; 81: 463.
26. Zapata C, Alvarez G. On Fisher's exact test for detecting gametic disequilibrium between DNA polymorphisms. Ann Hum Genet 1997; 61: 71-77.
27. Kahn HA. Relative risk and odds ratio. In: An introduction to epidemiologic methods. Oxford University Press, 1983: 38-55.
28. Hornyak Tj, Shafer JA. Role of calcium ion in the generation of factor XIII activity. Biochemistry 1991; 30: 6175-6182.
29. Ames PR, Iannaccone L, Alves JD, et al. Factor XIII in primary antiphospholipid syndrome. J Rheumatol 2005:32: 1058-1062.
30. Wilmer M, Rudin K, Kolde HJ, et al. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII VaL34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res 2001; 102: 81-91.
31. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem 2004; 112:223-228.
32. Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566.
33. Vossen CY, Rosendaal FR. The protective effect of the factor XIII Va134Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J Thromb Haemost 2005; 3: 1102-1103.
34. Boekholdt SM, Sandhu MS, Wareham NJ, et al. Fibrinogen plasma levels modify the association between the factor XIII Va134Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J Thromb Haemost 2006; 4: 2204-2209.
35. Bereczky Z, Balogh E, Katona E, et al. Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Va134Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res 2007; 120: 567-573.